Janssen reveals vital niraparib data
Research concerns the effect of niraparib when combined with abiraterone acetate plus prednisone
Read More
Tag: niraparib
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
Read More
Success for GSK’s Zejula in ovarian cancer
The drug was found to demonstrate significant improvement in progression free survival for women regardless of their biomarker status.
Read More
GSK adds to cancer offering with $5.1bn Tesaro buy
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.
Read More
Four new medicines cleared for use on NHS Scotland
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read More
EU approves post-chemo option for patients with ovarian cancer
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
